329 related articles for article (PubMed ID: 19047148)
1. The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.
Vander Griend DJ; Karthaus WL; Dalrymple S; Meeker A; DeMarzo AM; Isaacs JT
Cancer Res; 2008 Dec; 68(23):9703-11. PubMed ID: 19047148
[TBL] [Abstract][Full Text] [Related]
2. Human α(2)β(1)(HI) CD133(+VE) epithelial prostate stem cells express low levels of active androgen receptor.
Williamson SC; Hepburn AC; Wilson L; Coffey K; Ryan-Munden CA; Pal D; Leung HY; Robson CN; Heer R
PLoS One; 2012; 7(11):e48944. PubMed ID: 23145034
[TBL] [Abstract][Full Text] [Related]
3. Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.
Miki J; Furusato B; Li H; Gu Y; Takahashi H; Egawa S; Sesterhenn IA; McLeod DG; Srivastava S; Rhim JS
Cancer Res; 2007 Apr; 67(7):3153-61. PubMed ID: 17409422
[TBL] [Abstract][Full Text] [Related]
4. Expression profiling of CD133+ and CD133- epithelial cells from human prostate.
Shepherd CJ; Rizzo S; Ledaki I; Davies M; Brewer D; Attard G; de Bono J; Hudson DL
Prostate; 2008 Jun; 68(9):1007-24. PubMed ID: 18398820
[TBL] [Abstract][Full Text] [Related]
5. Growth kinetics of CD133-positive prostate cancer cells.
Reyes EE; Kunovac SK; Duggan R; Kregel S; Vander Griend DJ
Prostate; 2013 May; 73(7):724-33. PubMed ID: 23138940
[TBL] [Abstract][Full Text] [Related]
6. The role of androgen in determining differentiation and regulation of androgen receptor expression in the human prostatic epithelium transient amplifying population.
Heer R; Robson CN; Shenton BK; Leung HY
J Cell Physiol; 2007 Sep; 212(3):572-8. PubMed ID: 17541959
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer.
Pellacani D; Packer RJ; Frame FM; Oldridge EE; Berry PA; Labarthe MC; Stower MJ; Simms MS; Collins AT; Maitland NJ
Mol Cancer; 2011 Jul; 10():94. PubMed ID: 21801380
[TBL] [Abstract][Full Text] [Related]
8. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.
Chen YS; Wu MJ; Huang CY; Lin SC; Chuang TH; Yu CC; Lo JF
PLoS One; 2011; 6(11):e28053. PubMed ID: 22140506
[TBL] [Abstract][Full Text] [Related]
9. Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status.
Taylor RA; Toivanen R; Frydenberg M; Pedersen J; Harewood L; ; Collins AT; Maitland NJ; Risbridger GP
Stem Cells; 2012 Jun; 30(6):1087-96. PubMed ID: 22593016
[TBL] [Abstract][Full Text] [Related]
10. CD133 glycosylation is enhanced by hypoxia in cultured glioma stem cells.
Lehnus KS; Donovan LK; Huang X; Zhao N; Warr TJ; Pilkington GJ; An Q
Int J Oncol; 2013 Mar; 42(3):1011-7. PubMed ID: 23340741
[TBL] [Abstract][Full Text] [Related]
11. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
[TBL] [Abstract][Full Text] [Related]
12. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
Bidlingmaier S; Zhu X; Liu B
J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
[TBL] [Abstract][Full Text] [Related]
13. The characterization of epithelial and stromal subsets of candidate stem/progenitor cells in the human adult prostate.
Ceder JA; Jansson L; Ehrnström RA; Rönnstrand L; Abrahamsson PA
Eur Urol; 2008 Mar; 53(3):524-31. PubMed ID: 18053634
[TBL] [Abstract][Full Text] [Related]
14. Characterization of benign and malignant prostate epithelial Hoechst 33342 side populations.
Brown MD; Gilmore PE; Hart CA; Samuel JD; Ramani VA; George NJ; Clarke NW
Prostate; 2007 Sep; 67(13):1384-96. PubMed ID: 17639507
[TBL] [Abstract][Full Text] [Related]
15. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
Rentala S; Mangamoori LN
J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
[TBL] [Abstract][Full Text] [Related]
16. CD49f is an efficient marker of monolayer- and spheroid colony-forming cells of the benign and malignant human prostate.
Yamamoto H; Masters JR; Dasgupta P; Chandra A; Popert R; Freeman A; Ahmed A
PLoS One; 2012; 7(10):e46979. PubMed ID: 23071686
[TBL] [Abstract][Full Text] [Related]
17. Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells.
Gao J; Arnold JT; Isaacs JT
Cancer Res; 2001 Jul; 61(13):5038-44. PubMed ID: 11431338
[TBL] [Abstract][Full Text] [Related]
18. Dysplasia of human prostate CD133(hi) sub-population in NOD-SCIDS is blocked by c-myc anti-sense.
Goodyear SM; Amatangelo MD; Stearns ME
Prostate; 2009 May; 69(7):689-98. PubMed ID: 19143028
[TBL] [Abstract][Full Text] [Related]
19. Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells.
Vander Griend DJ; D'Antonio J; Gurel B; Antony L; Demarzo AM; Isaacs JT
Prostate; 2010 Jan; 70(1):90-9. PubMed ID: 19790235
[TBL] [Abstract][Full Text] [Related]
20. Prospective identification of tumorigenic prostate cancer stem cells.
Collins AT; Berry PA; Hyde C; Stower MJ; Maitland NJ
Cancer Res; 2005 Dec; 65(23):10946-51. PubMed ID: 16322242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
